Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase IIa, randomised, double-blind, double-dummy, parallel group, multi-centre study in subjects diagnosed with moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00642148
- Testing
- GW856553, Seretide
- Where
- 31 sites in Estonia, Finland and 10 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF 6001 after single and multiple doses in healthy volunteers.
- Trial name
- NCT01703052
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive…
- Trial name
- NCT02249247
- Testing
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 577 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00240435
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 25 sites in United States, Canada
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Functional Respiratory Imaging Study (FRI)
The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients
- Trial name
- FRI (NCT03268226)
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Where
- 5 sites in Belgium, Hungary
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Traumatic Brain Injury
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury…
- Trial name
- NCT04063215
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences LLC
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease.
- Trial name
- NCT04155047
- Testing
- Glyocopyrrolate Inhalation Solution administered by Magnair
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sunovion Respiratory Development Inc.
Asthma, COPD
Breathing Parameter Measurements for Lung Deposition Simulation
This study aims to simulate the deposition of aerosol drugs within the airways of asthma and COPD patients based on realistic breathing patterns measured at different pulmonology centers.
- Trial name
- CHOICE (NCT05445349)
- Testing
- Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
- Where
- 3 sites in Hungary
- Volunteers
- 163 people
- Sponsor
- Medisol Development Kft.
Pulmonary Disease, Chronic Obstructive
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of…
- Trial name
- COPD nDPI (NCT01316887)
- Testing
- 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 563 people
- Sponsor
- GlaxoSmithKline
Wounds
Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds
The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer…
- Trial name
- NCT04745806
- Testing
- ActiGraft
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- RedDress Ltd.
COPD
Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
The study is performed to investigate the effect of the spacing device on the pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without Aerochamber Plus Flow-vu antistatic VHC spacer as a single…
- Trial name
- TRIPLE 4 (NCT02119234)
- Testing
- Beclometasone/formoterol/glycopyrrolate
- Where
- Poland
- Volunteers
- 36 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Study in Patients With COPD
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
- Trial name
- NCT00215449
- Testing
- Formoterol Fumarate
- Where
- 68 sites in United States
- Volunteers
- 690 people
- Sponsor
- Dey
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic…
- Trial name
- NCT00224055
- Testing
- Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Watson Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities
The purpose of this study is to investigate the effects of Chronic Obstructive Pulmonary Disease (COPD) on daily life activities in patients with COPD and also to determine the socio-demographic profile, daily life style and…
- Trial name
- COPD LIFE (NCT01325948)
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 497 people
- Sponsor
- AstraZeneca
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
RSV
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection.
- Trial name
- RESOLVE (NCT07908381)
- Testing
- zelicapavir
- Where
- 4 sites in United States
- Volunteers
- 860 people
- Sponsor
- Enanta Pharmaceuticals, Inc
COPD
A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Evaluate Quality Improvement and Oxygen Utilization Improvements. 1.
- Trial name
- BRVB-OCD (NCT02627599)
- Testing
- Breath Responsive Variable Bolus Oxygen Conserving Device
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- StratiHealth
Chronic Obstructive Pulmonary Disease
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
- Trial name
- AERIFY-3 (NCT05326412)
- Testing
- Itepekimab SAR440340
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.